Vetglory

Vetglory is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of innovative therapeutics for companion animals. The company leverages a proprietary platform to discover and develop species-specific monoclonal antibodies and small molecules targeting high-prevalence conditions in dogs and cats, such as atopic dermatitis and osteoarthritis pain. Vetglory's lead programs include an anti-IL-31 antibody for canine skin allergies and an anti-NGF antibody for chronic pain management. By focusing on the rapidly growing pet healthcare market, the company aims to provide high-quality, effective medical solutions that mirror the standards of human pharmaceutical development.